ML792 inhibits growth and TGF-β1-induced EMT of osteosarcoma cells via TGF-β1/Smad and PI3K/AKT pathways

References

• Baek SH, Ko JH, Lee JH, Kim C, Lee H, Nam D, Lee J, Lee S-G, Yang WM, Um J-Y, et al. 2017. Ginkgolic acid inhibits invasion and migration and TGF-β-induced EMT of lung cancer cells through PI3K/Akt/mTOR inactivation. J Cell Physiol. 232(2):346–354. doi:10.1002/jcp.25426.
   PubMed Web of Science ®Google Scholar
• Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. 2000. Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem. 275(47):36803–10. doi:10.1074/jbc.M005912200.
   PubMed Web of Science ®Google Scholar
• Bielack S, Carrle D, Casali PG. 2009. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 20 Suppl 4:iv137–9. doi:10.1093/annonc/mdp154.
   Google Scholar
• Bishop MW, Janeway KA, Gorlick R. 2016. Future directions in the treatment of osteosarcoma. Curr Opin Pediatr. 28(1):26–33. doi:10.1097/MOP.0000000000000298.
   PubMed Web of Science ®Google Scholar
• Boudreau HE, Casterline BW, Rada B, Korzeniowska A, Leto TL. 2012. Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells. Free Radic Biol Med. 53(7):1489–99. doi:10.1016/j.freeradbiomed.2012.06.016.
   PubMed Web of Science ®Google Scholar
• Brandl M, Seidler B, Haller F, Adamski J, Schmid RM, Saur D, Schneider G. 2010. IKKα controls canonical TGFβ–SMAD signaling to regulate genes expressing SNAIL and SLUG during EMT in Panc1 cells. J Cell Sci. 123(Pt 24):4231–9. doi:10.1242/jcs.071100.
   PubMed Web of Science ®Google Scholar
• Bunney TD, Katan M. 2010. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer. 10(5):342–52. doi:10.1038/nrc2842.
   PubMed Web of Science ®Google Scholar
• Chanda A, Sarkar A, Bonni S. 2018. The SUMO system and TGFβ signaling interplay in regulation of epithelial-mesenchymal transition: implications for cancer progression. Cancers (Basel). 10(8). doi:10.3390/cancers10080264
   PubMed Web of Science ®Google Scholar
• David CJ, Huang YH, Chen M, Su J, Zou Y, Bardeesy N, Iacobuzio-Donahue C, Massagué J. 2016. TGF-β tumor suppression through a lethal EMT. Cell. 164(5):1015–30. doi:10.1016/j.cell.2016.01.009.
   PubMed Web of Science ®Google Scholar
• Dean DC, Shen S, Hornicek FJ, Duan Z. 2018. From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma. Cancer Metastasis Rev. 37(4):719–731. doi:10.1007/s10555-018-9763-8.
   PubMed Web of Science ®Google Scholar
• Du B, Shim JS. 2016. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules. 21(7). doi:10.3390/molecules21070965
   Web of Science ®Google Scholar
• Eccles SA, Welch DR. 2007. Metastasis: recent discoveries and novel treatment strategies. Lancet. 369(9574):1742–57. doi:10.1016/S0140-6736(07)60781-8.
   PubMed Web of Science ®Google Scholar
• Galindo-Hernandez O, Serna-Marquez N, Castillo-Sanchez R, Salazar EP. 2014. Extracellular vesicles from MDA-MB-231 breast cancer cells stimulated with linoleic acid promote an EMT-like process in MCF10A cells. Prostaglandins Leukot Essent Fatty Acids. 91(6):299–310. doi:10.1016/j.plefa.2014.09.002.
   PubMed Web of Science ®Google Scholar
• Geiss-Friedlander R, Melchior F. 2007. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 8(12):947–56. doi:10.1038/nrm2293.
   PubMed Web of Science ®Google Scholar
• Hao Y, Baker D, Ten Dijke P. 2019. TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci. 20(11). doi:10.3390/ijms20112767
   Web of Science ®Google Scholar
• He X, Riceberg J, Soucy T, Koenig E, Minissale J, Gallery M, Bernard H, Yang X, Liao H, Rabino C, et al. 2017. Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. Nat Chem Biol. 13(11):1164–1171. doi:10.1038/nchembio.2463.
   PubMed Web of Science ®Google Scholar
• Hendriks IA, Lyon D, Young C, Jensen LJ, Vertegaal ACO, Nielsen ML. 2017. Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation. Nat Struct Mol Biol. 24(3):325–336. doi:10.1038/nsmb.3366.
   PubMed Web of Science ®Google Scholar
• Ingham M, Schwartz GK. 2017. Cell-cycle therapeutics come of age. J Clin Oncol. 35(25):2949–2959. doi:10.1200/JCO.2016.69.0032.
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhang Z, Song C, Deng H, Yang R, Zhou L, Sun Y, Zhang Q. 2019. Glaucocalyxin a reverses EMT and TGF-β1-induced EMT by inhibiting TGF-β1/Smad2/3 signaling pathway in osteosarcoma. Chem Biol Interact. 307:158–166. doi:10.1016/j.cbi.2019.05.005.
   PubMed Web of Science ®Google Scholar
• Kim KI, Baek SH. 2009. International review of cell and molecular biology. Int Rev Cell Mol Biol. 273:265–311. doi:10.1016/S1937-6448(08)01807-8.
   PubMed Web of Science ®Google Scholar
• Knight ZA, Shokat KM. 2007. Chemically targeting the PI3K family. Biochem Soc Trans. 35(Pt 2):245–9. doi:10.1042/BST0350245.
   PubMedGoogle Scholar
• Kroonen JS, Kruisselbrink AB, Briaire-de Bruijn IH, Olaofe Olaejirinde O, Bovée Judith VMG, Vertegaal Alfred CO. 2021. SUMOylation is associated with aggressive behavior in chondrosarcoma of bone. Cancers (Basel). 13(15). doi:10.3390/cancers13153823
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. 2014. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15(3):178–96. doi:10.1038/nrm3758.
   PubMed Web of Science ®Google Scholar
• Liu S, Long J, Yuan B, Zheng M, Xiao M, Xu J, Lin X, Feng X-H. 2016. SUMO modification reverses inhibitory effects of smad nuclear interacting protein-1 in TGF-β responses. J Biol Chem. 291(47):24418–24430. doi:10.1074/jbc.M116.755850.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wang H, Mills GB. 2003. Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol. 7(2):205–28.
   PubMedGoogle Scholar
• Luo J, Yao JF, Deng XF, Zheng X-D, Jia M, Wang Y-Q, Huang Y, Zhu J-H. 2018. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling. J Exp Clin Cancer Res. 37(1):23. doi:10.1186/s13046-018-0694-6.
   PubMedGoogle Scholar
• Mendonsa AM, Na TY, Gumbiner BM. 2018. E-cadherin in contact inhibition and cancer. Oncogene. 37(35):4769–4780. doi:10.1038/s41388-018-0304-2.
   PubMed Web of Science ®Google Scholar
• Meng XM, Nikolic-Paterson DJ, Lan HY. 2016. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 12(6):325–38. doi:10.1038/nrneph.2016.48.
   PubMed Web of Science ®Google Scholar
• Moustakas A, Heldin CH. 2007. Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 98(10):1512–20. doi:10.1111/j.1349-7006.2007.00550.x.
   PubMed Web of Science ®Google Scholar
• Padua D, Massagué J. 2009. Roles of TGFβ in metastasis. Cell Res. 19(1):89–102. doi:10.1038/cr.2008.316.
   PubMed Web of Science ®Google Scholar
• Pastushenko I, Blanpain C. 2019. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 29(3):212–226. doi:10.1016/j.tcb.2018.12.001.
   PubMed Web of Science ®Google Scholar
• Reidick C, El Magraoui F, Meyer HE, Stenmark H, Platta H. 2015. Regulation of the tumor-suppressor function of the class III phosphatidylinositol 3-kinase complex by ubiquitin and SUMO. Cancers (Basel). 7(1):1–29. doi:10.3390/cancers7010001.
   Web of Science ®Google Scholar
• Roberts AB, Tian F, Byfield SD, Stuelten C, Ooshima A, Saika S, Flanders K. 2006. Smad3 is key to TGF-β-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev.17(1-2):19–27. doi:10.1016/j.cytogfr.2005.09.008.
   PubMed Web of Science ®Google Scholar
• Schneekloth JS Jr. 2017. Controlling protein SUMOylation. Nat Chem Biol. 13(11):1141–1142. doi:10.1038/nchembio.2496.
   PubMed Web of Science ®Google Scholar
• Seeler JS, Dejean A. 2017. SUMO and the robustness of cancer. Nat Rev Cancer. 17(3):184–197. doi:10.1038/nrc.2016.143.
   PubMed Web of Science ®Google Scholar
• Tu B, Peng ZX, Fan QM, Du L, Yan W, Tang T-T. 2014. Osteosarcoma cells promote the production of pro-tumor cytokines in mesenchymal stem cells by inhibiting their osteogenic differentiation through the TGF-β/Smad2/3 pathway. Exp Cell Res. 320(1):164–73. doi:10.1016/j.yexcr.2013.10.013.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang K, Wang R, Liu X. 2018. SUMOylation regulates TGF-β1/Smad4 signalling in-resistant glioma cells. Anticancer Drugs. 29(2):136–144. doi:10.1097/CAD.0000000-000000578.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhu S, Ding Y, Beck WT, Mo Y-Y. 2009. MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin Cancer Res. 15(5):1550–7. doi:10.1158/1078-0432.CCR-08-0820.
   PubMed Web of Science ®Google Scholar
• Xu J, Lamouille S, Derynck R. 2009. TGF-β-induced epithelial to mesenchymal transition. Cell Res. 19(2):156–72. doi:10.1038/cr.2009.5.
   PubMed Web of Science ®Google Scholar
• Xu P, Lin X, Feng XH. 2016. Posttranslational regulation of Smads. Cold Spring Harb Perspect Biol. 8(12). doi:10.1101/cshperspect.a022087
   PubMed Web of Science ®Google Scholar
• Yang Y, Liang Z, Xia Z, Wang X, Ma Y, Sheng Z, Gu Q, Shen G, Zhou L, Zhu H, et al. 2019a. SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways. Cell Commun Signal. 17(1):82. doi:10.1186/s12964-019-0392-9.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang P, Yan R, et al. 2019b. MnTE-2-PyP attenuates TGF-β-induced epithelial-mesenchymal transition of colorectal cancer cells by inhibiting the Smad2/3 signaling pathway. Oxid Med Cell Longev. 2019:8639791. doi:10.1155/2019/8639791.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Tan X, Zhao A, Zhu L, Yin B, Yuan J, Qiang B, Peng X. 2012. microRNA-214-mediated UBC9 expression in glioma. BMB Rep. 45(11):641–6. doi:10.5483/BMBRep.2012.45.11.097.
   PubMed Web of Science ®Google Scholar